文献速递乳腺癌

全基因组测序驱动的循环肿瘤DNA测序用于乳腺癌检测

Whole genome sequencing-powered ctDNA sequencing for breast cancer detection.
PubMed 文献 · Ann Oncol · 2025-02-04

该研究采用基于全基因组测序(WGS)的肿瘤信息指导的循环肿瘤DNA(ctDNA)平台,分析了78例早期乳腺癌患者的617份血浆样本。中位随访76个月,ctDNA检测与未来复发高风险(P<0.0001)和总生存期缩短(P<0.0001)相关,从ctDNA检测到临床复发的中位提前时间为15个月。所有复发患者(11/11)均检出MRD,而未检出ctDNA的患者(64/64)均未复发。

要点

  • 全基因组测序驱动的MRD检测可较临床复发提前中位15个月发现乳腺癌复发。
  • ctDNA检测与未来复发高风险(P<0.0001)和总生存期缩短(P<0.0001)显著相关。
  • 诊断时ctDNA检出率为98%(49/50),高于外显子组测序指导的检测方法。

核心结论

  • 基于全基因组测序的MRD检测方法能以较临床复发更长的提前时间检出乳腺癌复发,并与无复发生存期强相关。
  • 诊断时ctDNA检出率高于外显子组测序指导的肿瘤信息检测方法所报告的水平。

研究设计与样本

  • 研究分析了78例早期乳腺癌患者(23例三阴性、35例HER2阳性、18例激素受体阳性、2例未知)的617份血浆样本(中位8份,范围2-14份)。
  • 样本采集时间包括诊断时治疗前、新辅助化疗第2周期、新辅助治疗后手术后(若接受)、第一年每3个月及之后每6个月。
  • 血浆DNA采用NeXT Personal MRD平台分析,该平台为肿瘤信息指导的全基因组测序方法,构建个体化ctDNA测序面板,中位追踪每例患者1451个变异。

主要发现

  • ctDNA检出水平范围为2.19 PPM至204900 PPM(中位405 PPM),所有ctDNA检出中39%处于<100 PPM的超低范围。
  • 在有诊断时样本的患者中,98%(49/50)在治疗前检出ctDNA。
  • 中位随访76个月(范围5-118个月)时,ctDNA检出与未来复发高风险相关(P<0.0001;log-rank检验)并与总生存期缩短相关(P<0.0001),从ctDNA检测到临床复发的中位提前时间为15个月(范围0.9-61.5个月)。
  • 复发患者中100%(11/11)检出MRD,首次MRD检测时ctDNA中位水平为13.1 PPM;未检出ctDNA的患者在整个随访期间均未复发(64/64)。
  • 与外显子组驱动的MRD检测方法比较,显示出更高的敏感性和更长的提前时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumour DNA (ctDNA)-based detection of molecular residual disease (MRD) presents a strategy to identify patients at high risk of relapse. In this article, we profile early breast cancer patients with an ultrasensitive, whole genome sequencing (WGS)-based, tumour-informed ctDNA platform. MATERIALS AND METHODS: We analysed 617 plasma samples (median 8, range 2-14) from 78 patients (23 triple-negative breast cancer, 35 human epidermal growth factor receptor 2-positive, 18 hormone receptor-positive, and 2 unknown). Samples were collected at diagnosis before therapy, cycle 2 of neoadjuvant chemotherapy, post-surgery after neoad'juvant therapy if administered, every 3 months during the first year, and every 6 months thereafter. Plasma DNA was analysed using the NeXT Personal MRD platform, a tumour-informed WGS approach to produce personalized ctDNA sequencing panels tracking a median of 1451 variants per patient. MRD detection was correlated with clinical outcomes. RESULTS: ctDNA was detected at levels ranging from 2.19 parts per million (PPM) to 204 900 PPM (median 405 PPM), with 39% of all ctDNA detections in the ultra-low range <100 PPM. Of patients with samples at diagnosis, 98% (49/50) had ctDNA detected before treatment. At a median follow-up of 76 months (range 5-118 months), detection of ctDNA was associated with high risk of future relapse (P < 0.0001; log-rank test) and shortened overall survival (P < 0.0001) with a median lead time from ctDNA detection to clinical relapse of 15 months (range 0.9-61.5 months). MRD was identified in 100% (11/11) of patients who relapsed, with a median level of ctDNA at first MRD detection of 13.1 PPM. No ctDNA-undetected patients relapsed throughout follow-up (64/64). Comparison with exome-powered MRD detection assays showed improved sensitivity and lead time. CONCLUSIONS: A whole genome-powered MRD assay detected breast cancer relapse with a long lead time over clinical relapse, and was strongly associated with relapse-free survival. Rates of ctDNA detection at diagnosis were higher than those reported with exome-based tumour-informed assays.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Garcia-Murillas I, Abbott CW, Cutts RJ, et al. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Ann Oncol. 2025. PMID: 39914664. doi:10.1016/j.annonc.2025.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。